TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Contineum Therapeutics, Inc. Class A ( (CTNM) ) has shared an update.
On November 20, 2025, Contineum Therapeutics reported topline data from its Phase 2 VISTA trial of PIPE-307 for treating relapsing-remitting multiple sclerosis (RRMS). The trial showed that PIPE-307 had an acceptable safety and tolerability profile but did not meet its primary or secondary efficacy endpoints, as no significant change was observed in binocular 2.5% low contrast letter acuity. Despite the disappointing results, Contineum remains committed to developing therapies for inflammatory and fibrotic diseases and plans to present the complete dataset at a future medical meeting.
The most recent analyst rating on (CTNM) stock is a Buy with a $25.00 price target. To see the full list of analyst forecasts on Contineum Therapeutics, Inc. Class A stock, see the CTNM Stock Forecast page.
Spark’s Take on CTNM Stock
According to Spark, TipRanks’ AI Analyst, CTNM is a Underperform.
Contineum Therapeutics, Inc. receives a low stock score due to significant financial struggles, including a lack of revenue and negative profitability. The technical analysis reveals a bearish trend, and the valuation is weak with a negative P/E ratio. While there are some positives in terms of debt reduction and cash reserves, these are overshadowed by the company’s operational challenges and weak market momentum.
To see Spark’s full report on CTNM stock, click here.
More about Contineum Therapeutics, Inc. Class A
Contineum Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel, oral small molecule therapies for neuroscience, inflammation, and immunology indications with significant unmet needs. The company is advancing a pipeline of internally-developed programs, including PIPE-791 for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307 for relapsing-remitting multiple sclerosis and major depressive disorder.
Average Trading Volume: 173,379
Technical Sentiment Signal: Buy
Current Market Cap: $366.9M
For an in-depth examination of CTNM stock, go to TipRanks’ Overview page.